文献速递前列腺癌

PSMA PET/CT 与传统影像在初诊中高危前列腺癌初始分期中的比较:一项回顾性单中心研究

Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
PubMed 文献 · Eur Urol Oncol · 2020-09-18

该研究基于前瞻性单臂试验(NCT03368547)的回顾性队列,纳入168例未接受治疗的中危和高危前列腺癌患者,比较PSMA PET/CT与传统影像在初始分期中的一致性。结果显示N、M1a、M1b、M1c分期的不一致率分别为21.0%、7.1%、8.7%、1.4%,PSMA PET/CT使22.0%患者分期升高、7.1%分期降低。结论认为PSMA PET/CT可能是初诊中高危前列腺癌初始分期的有价值的工具。

要点

  • PSMA PET/CT与传统影像在N分期的不一致率为21.0%,在M1a、M1b、M1c分别为7.1%、8.7%、1.4%。
  • PSMA PET/CT使22.0%患者分期升高,7.1%患者分期降低。
  • 在50例接受根治性前列腺切除加盆腔淋巴结清扫的患者中,PSMA PET/CT阳性淋巴结患病率为14%,传统影像为4%,假阴性率分别为30%和32%。

核心结论

  • PSMA PET/CT可能是未接受治疗的中危和高危前列腺癌初始分期的有价值的工具。

研究设计与样本

  • 回顾性队列研究,作为前瞻性单臂试验(NCT03368547)的事后分析。
  • 纳入168例未接受治疗的中危和高危前列腺癌患者,其中高危占124/168(73.8%)。
  • 患者在前列腺特异性抗原中位值11.4(6.8-24.6)ng/ml条件下,于传统影像检查后6个月内接受PSMA PET/CT。

主要发现

  • PSMA PET/CT与传统影像在N、M1a、M1b、M1c分期的不一致率分别为34/162(21.0%)、5/70(7.1%)、8/92(8.7%)、1/71(1.4%)。
  • PSMA PET/CT使37/168(22.0%)患者分期升高,12/170(7.1%)患者分期降低。
  • 在50例接受根治性前列腺切除加盆腔淋巴结清扫的患者中,PSMA PET/CT阳性淋巴结患病率为14%,传统影像为4%,假阴性率分别为30%和32%。

临床怎么用

  • 对于未接受治疗的中危和高危前列腺癌患者,可考虑使用PSMA PET/CT进行初始分期以更准确地识别或排除转移灶。
  • PSMA PET/CT可能改变部分患者的分期,从而影响治疗决策。

局限性

  • 传统影像模态存在异质性。
  • 传统影像与PSMA PET/CT之间的时间间隔可达6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging in the initial staging of men with prostate cancer (PCa) has yet to be evaluated adequately. OBJECTIVE: To investigate the concordance of PSMA PET/CT with conventional imaging (CI) with cross-sectional abdominopelvic and/or radionuclide bone imaging in the initial staging of patients with treatment-naïve PCa. DESIGN, SETTING, AND PARTICIPANTS: We performed a post hoc retrospective cohort study of patients enrolled in a prospective single-arm trial (NCT03368547). We included patients with intermediate-risk (IR) and high-risk (HR) PCa who underwent PSMA PET/CT within 6 mo of CI. Patients with any treatment prior to PSMA PET/CT were excluded. Patient- and tumor-specific data, and imaging findings were obtained. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Our primary outcome measurement was the concordance rate of PSMA PET/CT with CI for the identification of N, M1a, M1b, and M1c disease. Descriptive statistics were used. RESULTS AND LIMITATIONS: A total of 168 patients with treatment-naïve IR and HR PCa met the inclusion criteria. HR disease accounted for 124/168 (73.8%) patients. The median prostate-specific antigen was 11.4 (6.8-24.6)ng/ml. The rates of nonconcordance between PSMA PET/CT and CI were 34/162 (21.0%), 5/70 (7.1%), 8/92 (8.7%), and 1/71 (1.4%) for N, M1a, M1b, and M1c disease, respectively. PSMA PET/CT assigned a higher stage in 37/168 (22.0%) patients and a lower stage in 12/170 (7.1%) patients. In a subset of 50 patients treated with radical prostatectomy and pelvic lymph node dissection, the prevalence of PSMA PET/CT-positive and that of CI-positive nodal disease were 14% and 4%, and the false negative rates were 30% and 32%, respectively. The principal limitations of this study include the heterogeneity in CI modalities and the 6-mo time frame between CI and PSMA PET. CONCLUSIONS: PSMA PET/CT imaging may serve as a valuable tool in the initial staging of treatment-naïve IR and HR PCa. PATIENT SUMMARY: We evaluated how prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) compared with standard imaging (such as computed tomography, bone scan, and prostate magnetic resonance imaging) for initial staging of patients with prostate cancer. Our findings suggest that PSMA PET/CT may detect and rule out more metastatic lesions, which could prove valuable in guiding treatment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lenis AT, Pooli A, Lec PM, et al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2020. PMID: 32958451. doi:10.1016/j.euo.2020.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。